EGFR and non-small cell lung carcinoma: While BSA-based and body weight (BW)-based dose adjustments are made for chemotherapy with cytotoxic agents and bevacizumab-based chemotherapy, respectively, it is unknown whether BSA- or BW-based dose adjustments could affect gefitinib efficacy in patients with NSCLC harboring EGFR mutations.